{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:08:32Z","timestamp":1794049712413,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K015524\/1"],"award-info":[{"award-number":["MR\/K015524\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N0137941\/1"],"award-info":[{"award-number":["MR\/N0137941\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Chronic cannabis use is associated with impaired cognitive function. Evidence indicates cannabidiol (CBD) might be beneficial for treating cannabis use disorder. CBD may also have pro-cognitive effects; however, its effect on cognition in people with cannabis use disorder is currently unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aimed to assess whether a 4-week CBD treatment impacted cognitive function. We hypothesised that CBD treatment would improve cognition from baseline to week 4, compared to placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cognition was assessed as a secondary outcome in a phase 2a randomised, double-blind, parallel-group and placebo-controlled clinical trial of 4-week daily 200\u00a0mg, 400\u00a0mg and 800\u00a0mg CBD for the treatment of cannabis use disorder. Participants had moderate or severe DSM-5 cannabis use disorder and intended to quit cannabis use. Our pre-registered primary cognitive outcome was delayed prose recall. Secondary cognitive outcomes were immediate prose recall, stop signal reaction time, trail-making task performance, verbal fluency and digit span.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy participants were randomly assigned to placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923), 400\u00a0mg CBD (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200924) and 800\u00a0mg CBD (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923). A 200\u00a0mg group was eliminated from the trial because it was an inefficacious dose at interim analysis (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912) and was not analysed here. For the primary cognitive outcome, there was no effect of CBD compared to placebo, evidenced by a lack of dose-by-time interaction at 400\u00a0mg (0.46, 95%CIs:\u2009\u2212\u20091.41, 2.54) and 800\u00a0mg (0.89, 95%CIs:\u2009\u2212\u20090.99, 2.81). There was no effect of CBD compared to placebo on secondary cognitive outcomes, except backwards digit span which increased following 800\u00a0mg CBD (0.30, 95%CIs: 0.02, 0.58).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this clinical trial for cannabis use disorder, CBD did not influence delayed verbal memory. CBD did not have broad cognitive effects but 800\u00a0mg daily treatment may improve working memory manipulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>The trial was registered with ClinicalTrials.gov (NCT02044809) and the EU Clinical Trials Register (2013\u2013000,361-36).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00213-022-06303-5","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T10:03:32Z","timestamp":1672826612000},"page":"337-346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder"],"prefix":"10.1007","volume":"240","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4787-1789","authenticated-orcid":false,"given":"Rachel","family":"Lees","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey A.","family":"Hines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandni","family":"Hindocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Baio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha D. C.","family":"Shaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Stothart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mofeez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia J. A.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Valerie","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom P.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"issue":"2","key":"6303_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/ADM.0000000000000372","volume":"12","author":"E Aharonovich","year":"2018","unstructured":"Aharonovich E, Campbell ANC, Shulman M, Hu M-C, Kyle T, Winhusen T, Nunes EV (2018) Neurocognitive profiling of adult treatment seekers enrolled in a clinical trial of a web-delivered intervention for substance use disorders. J Addict Med 12(2):99\u2013106. https:\/\/doi.org\/10.1097\/ADM.0000000000000372","journal-title":"J Addict Med"},{"issue":"9","key":"6303_CR2","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1177\/0269881120936419","volume":"34","author":"MAP Bloomfield","year":"2020","unstructured":"Bloomfield MAP, Green SF, Hindocha C, Yamamori Y, Yim JLL, Jones APM, Walker HR, Tokarczuk P, Statton B, Howes OD, Curran HV, Freeman TP (2020) The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: an arterial spin labelling magnetic resonance imaging study. J Psychopharmacol 34(9):981\u2013989. https:\/\/doi.org\/10.1177\/0269881120936419","journal-title":"J Psychopharmacol"},{"issue":"7","key":"6303_CR3","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","volume":"235","author":"DL Boggs","year":"2018","unstructured":"Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D\u2019Souza DC, Ranganathan M (2018) The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology 235(7):1923\u20131932. https:\/\/doi.org\/10.1007\/s00213-018-4885-9","journal-title":"Psychopharmacology"},{"issue":"7","key":"6303_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.biopsych.2015.12.002","volume":"79","author":"SJ Broyd","year":"2016","unstructured":"Broyd SJ, van Hell HH, Beale C, Y\u00fccel M, Solowij N (2016) Acute and chronic effects of cannabinoids on human cognition\u2014a systematic review. Cannabinoids Psychotic Disord 79(7):557\u2013567. https:\/\/doi.org\/10.1016\/j.biopsych.2015.12.002","journal-title":"Cannabinoids Psychotic Disord"},{"issue":"4","key":"6303_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/dar.12922","volume":"38","author":"CJWH Bruijnen","year":"2019","unstructured":"Bruijnen CJWH, Dijkstra BAG, Walvoort SJW, Markus W, VanDerNagel JEL, Kessels RPC, Jong DE, C. A. J. (2019) Prevalence of cognitive impairment in patients with substance use disorder. Drug Alcohol Rev 38(4):435\u2013442. https:\/\/doi.org\/10.1111\/dar.12922","journal-title":"Drug Alcohol Rev"},{"issue":"5","key":"6303_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrn.2016.28","volume":"17","author":"HV Curran","year":"2016","unstructured":"Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJA, Parsons LH (2016) Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci 17(5):293\u2013306. https:\/\/doi.org\/10.1038\/nrn.2016.28","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"6303_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s42238-020-00034-0","volume":"2","author":"T Curran","year":"2020","unstructured":"Curran T, Devillez H, YorkWilliams SL, Bidwell LC (2020) Acute effects of naturalistic THC vs CBD use on recognition memory: a preliminary study. J Cannabis Res 2(1):28. https:\/\/doi.org\/10.1186\/s42238-020-00034-0","journal-title":"J Cannabis Res"},{"key":"6303_CR8","doi-asserted-by":"publisher","unstructured":"Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, Whiteford H, Leung J, Naghavi M, Griswold M, Rehm J, Hall W, Sartorius B, Scott J, Vollset SE, Knudsen AK, Haro JM, Patton G, Kopec J, \u2026 Vos T (2018) The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatr, 5(12), 987\u20131012https:\/\/doi.org\/10.1016\/S2215-0366(18)30337-7","DOI":"10.1016\/S2215-0366(18)30337-7"},{"issue":"1","key":"6303_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0269881112460109","volume":"27","author":"A Englund","year":"2013","unstructured":"Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D, Feilding A, Walker L, Murray RM, Kapur S (2013) Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 27(1):19\u201327. https:\/\/doi.org\/10.1177\/0269881112460109","journal-title":"J Psychopharmacol"},{"key":"6303_CR10","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.neubiorev.2019.09.036","volume":"107","author":"AM Freeman","year":"2019","unstructured":"Freeman AM, Petrilli K, Lees R, Hindocha C, Mokrysz C, Curran HV, Saunders R, Freeman TP (2019) How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci Biobehav Rev 107:696\u2013712. https:\/\/doi.org\/10.1016\/j.neubiorev.2019.09.036","journal-title":"Neurosci Biobehav Rev"},{"issue":"10","key":"6303_CR11","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","volume":"7","author":"TP Freeman","year":"2020","unstructured":"Freeman TP, Hindocha C, Baio G, Shaban NDC, Thomas EM, Astbury D, Freeman AM, Lees R, Craft S, Morrison PD, Bloomfield MAP, O\u2019Ryan D, Kinghorn J, Morgan CJA, Mofeez A, Curran HV (2020) Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatr 7(10):865\u2013874. https:\/\/doi.org\/10.1016\/S2215-0366(20)30290-X","journal-title":"Lancet Psychiatr"},{"key":"6303_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jpsychires.2021.09.007","volume":"143","author":"J Hotz","year":"2021","unstructured":"Hotz J, Fehlmann B, Papassotiropoulos A, de Quervain DJF, Schicktanz NS (2021) Cannabidiol enhances verbal episodic memory in healthy young participants: a randomized clinical trial. J Psychiatr Res 143:327\u2013333. https:\/\/doi.org\/10.1016\/j.jpsychires.2021.09.007","journal-title":"J Psychiatr Res"},{"issue":"3","key":"6303_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1017\/S0033291720005449","volume":"51","author":"R Lees","year":"2021","unstructured":"Lees R, Hines LA, D\u2019Souza DC, Stothart G, Di Forti M, Hoch E, Freeman TP (2021) Psychosocial and pharmacological treatments for cannabis use disorder and mental health comorbidities: a narrative review. Psychol Med 51(3):353\u2013364. https:\/\/doi.org\/10.1017\/S0033291720005449","journal-title":"Psychol Med"},{"issue":"4","key":"6303_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1037\/pha0000326","volume":"28","author":"ME Lovell","year":"2020","unstructured":"Lovell ME, Akhurst J, Padgett C, Garry MI, Matthews A (2020) Cognitive outcomes associated with long-term, regular, recreational cannabis use in adults: a meta-analysis. Exp Clin Psychopharmacol 28(4):471\u2013494. https:\/\/doi.org\/10.1037\/pha0000326","journal-title":"Exp Clin Psychopharmacol"},{"issue":"7","key":"6303_CR15","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1038\/npp.2012.14","volume":"37","author":"BJ Mason","year":"2012","unstructured":"Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, Buffkins K, Kyle M, Adusumalli M, Begovic A, Rao S (2012) A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 37(7):1689\u20131698. https:\/\/doi.org\/10.1038\/npp.2012.14","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"6303_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S (2018) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 175(3):225\u2013231. https:\/\/doi.org\/10.1176\/appi.ajp.2017.17030325","journal-title":"Am J Psychiatry"},{"key":"6303_CR17","unstructured":"Miller, W. R., & Rollnick, S. (2012). Motivational interviewing: helping people change. Guilford press,\u00a0New York"},{"issue":"4","key":"6303_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1192\/bjp.bp.110.077503","volume":"197","author":"CJA Morgan","year":"2010","unstructured":"Morgan CJA, Schafer G, Freeman TP, Curran HV (2010) Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatr 197(4):285\u2013290. https:\/\/doi.org\/10.1192\/bjp.bp.110.077503. (Cambridge Core)","journal-title":"Br J Psychiatr"},{"issue":"9","key":"6303_CR19","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","volume":"38","author":"CJ Morgan","year":"2013","unstructured":"Morgan CJ, Das RK, Joye A, Curran HV, Kamboj SK (2013) Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 38(9):2433\u20132436","journal-title":"Addict Behav"},{"issue":"1","key":"6303_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41398-018-0191-x","volume":"8","author":"CJA Morgan","year":"2018","unstructured":"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8(1):181. https:\/\/doi.org\/10.1038\/s41398-018-0191-x","journal-title":"Transl Psychiatry"},{"key":"6303_CR21","doi-asserted-by":"publisher","unstructured":"Prud\u2019homme M, Cata R, Jutras-Aswad D (2015) Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Subst Abus: Res Treat 9, SART.S25081. https:\/\/doi.org\/10.4137\/SART.S25081","DOI":"10.4137\/SART.S25081"},{"key":"#cr-split#-6303_CR22.1","unstructured":"Reitan, R. M. (1986). Trail Making Test: Manual for administration and Scoring. Tuscon: Reitan Neuropsychology"},{"key":"#cr-split#-6303_CR22.2","unstructured":"Laboratory, 1992.\u00a0World Drug Report 2020 (United Nations publication, Sales No. E.20.XI.6)"},{"key":"6303_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.addbeh.2015.01.013","volume":"45","author":"A Roten","year":"2015","unstructured":"Roten A, Baker NL, Gray KM (2015) Cognitive performance in a placebo-controlled pharmacotherapy trial for youth with marijuana dependence. Addict Behav 45:119\u2013123. https:\/\/doi.org\/10.1016\/j.addbeh.2015.01.013","journal-title":"Addict Behav"},{"issue":"9","key":"6303_CR24","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/jama.287.9.1123","volume":"287","author":"N Solowij","year":"2002","unstructured":"Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, Christiansen K, McRee B, Vendetti J, for the Marijuana Treatment Project Research Group (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287(9):1123\u20131131. https:\/\/doi.org\/10.1001\/jama.287.9.1123","journal-title":"JAMA"},{"issue":"1","key":"6303_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/can.2017.0043","volume":"3","author":"N Solowij","year":"2018","unstructured":"Solowij N, Broyd SJ, Beale C, Prick J-A, Greenwood L-M, van Hell H, Suo C, Galettis P, Pai N, Fu S, Croft RJ, Martin JH, Y\u00fccel M (2018) Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial. Cannabis Cannabinoid Res 3(1):21\u201334. https:\/\/doi.org\/10.1089\/can.2017.0043","journal-title":"Cannabis Cannabinoid Res"},{"key":"6303_CR26","unstructured":"United Nations. (2020). World Drug Report 2020 (p. Sales No. E.20.XI.6)"},{"issue":"2","key":"6303_CR27","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3758\/BRM.40.2.479","volume":"40","author":"F Verbruggen","year":"2008","unstructured":"Verbruggen F, Logan GD, Stevens MA (2008) STOP-IT: Windows executable software for the stop-signal paradigm. Behav Res Methods 40(2):479\u2013483. https:\/\/doi.org\/10.3758\/BRM.40.2.479","journal-title":"Behav Res Methods"},{"key":"6303_CR28","unstructured":"Wechsler D (1997) WAIS-III administration and scoring manual.\u00a0Psychological Corporation,\u00a0San Antonio"},{"issue":"6","key":"6303_CR29","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/01688638908400940","volume":"11","author":"B Wilson","year":"1989","unstructured":"Wilson B, Cockburn J, Baddeley A, Hiorns R (1989) The development and validation of a test battery for detecting and monitoring everyday memory problems. J Clin Exp Neuropsychol 11(6):855\u2013870. https:\/\/doi.org\/10.1080\/01688638908400940","journal-title":"J Clin Exp Neuropsychol"},{"key":"6303_CR30","doi-asserted-by":"publisher","first-page":"110063","DOI":"10.1016\/j.pnpbp.2020.110063","volume":"104","author":"S Zhornitsky","year":"2021","unstructured":"Zhornitsky S, Pelletier J, Assaf R, Giroux S, Li CR, Potvin S (2021) Acute effects of partial CB1 receptor agonists on cognition \u2013 a meta-analysis of human studies. Prog Neuropsychopharmacol Biol Psychiatry 104:110063. https:\/\/doi.org\/10.1016\/j.pnpbp.2020.110063","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06303-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-022-06303-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06303-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T23:52:14Z","timestamp":1674777134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-022-06303-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["6303"],"URL":"https:\/\/doi.org\/10.1007\/s00213-022-06303-5","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"assertion":[{"value":"28 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published with omitted supplemental file.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CH became a full-time member of GW pharmaceuticals after the conclusion of the clinical trial. All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}